Develops an oral drug candidate intended to treat pulmonary arterial hypertension for people with the disease.
10-K for FY2025, filed Mar 26, 2026
Under its license to ABLi for risvodetinib, Inhibikase may receive development and regulatory milestone payments, plus royalties based on net sales.
10-K for FY2025, filed Mar 26, 2026In May 2025, we entered into a license agreement (the "License Agreement") with ABLi Therapeutics, Inc. ("ABLi"), pursuant to which we…View ↗
$3.7M
10-K for FY2025, filed Mar 26, 2026
$3.7M ↗No. It lost $48.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$20.5MView ↗
8-K, filed Aug 26, 2026
On August 21, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Inhibikase Therapeutics, Inc. (the “Company”)…View ↗
Growing. Revenue grew 20% in 4 years, from $3.1M in FY2021 to $3.7M in FY2025, about 5% a year.
Shift in therapeutic focus
The older report described a Parkinson's-focused pipeline and an imatinib prodrug program for chronic myeloid leukemia; the latest report centers on an imatinib prodrug for pulmonary arterial hypertension.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026We are a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary…View ↗
Risvodetinib licensing
The older report described its Parkinson's drug program as company-developed; the latest report says risvodetinib development is paused and the drug has been licensed to ABLi for global development and commercialization.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026We are a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease…View ↗
Competes with GlaxoSmithKline, Johnson and Johnson, United Therapeutics, Bayer Pharmaceuticals, Liquidia, Gilead Sciences, Merck and, Regeneron, Novartis Pharmaceuticals, Pfizer, Gossamer Bio, and Insmed
10-K for FY2025, filed Mar 26, 2026Our product candidate for treatment of PAH will compete with approved treatments as well as other therapies that may be in clinical or…View ↗
Loading...